Shohei Shigeto

NOTCH1 activating variants identify a high-risk subgroup of adenoid cystic carcinoma in a nationwide Japanese cohort

Abstract Adenoid cystic carcinoma (ACC) follows a heterogeneous clinical course, and because systemic therapies have limited efficacy, active surveillance is offered to selected patients, yet no validated molecular biomarker guides the choice between surveillance and intensive tr...